PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-25.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
610.74%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
609.26%
EPS growth of 609.26% while AVXL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
609.26%
Diluted EPS growth of 609.26% while AVXL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
OCF growth above 1.5x AVXL's 45.67%. David Dodd would confirm a clear edge in underlying cash generation.
320.27%
FCF growth above 1.5x AVXL's 45.67%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
419.54%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
400.10%
3Y OCF/share CAGR above 1.5x AVXL's 9.06%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
706.07%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
706.07%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
315.93%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
-251.89%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-251.89%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-24.04%
Negative 3Y equity/share growth while AVXL is at 5.10%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
Positive BV/share change while AVXL is negative. John Neff sees a clear edge over a competitor losing equity.
-14.44%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
30.71%
SG&A growth well above AVXL's 39.80%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.